Active Wound Care Market worth $4.50 billion by 2031 - Exclusive Report by MarketsandMarkets™

The global active wound care market is projected to grow from $3.19 billion in 2026 to $4.50 billion by 2031, a 7.1% CAGR, driven by chronic wounds, diabetes prevalence and adoption of regenerative therapies. Growth is increasingly shifting toward hospital, surgical, burns and trauma settings after CMS replaced product-specific Medicare skin-substitute reimbursement with a single 2026 payment rate of about $127.28, pressuring physician-office-dependent models. Strategic consolidation continues, including Solventum's $725 million cash acquisition of Acera Surgical and MIMEDX's proposed approximately $350 million acquisition of Sanara MedTech.

Analysis

The actionable signal is not category growth but a profit-pool reset: lower reimbursement intensity shifts value from physician-office distributors and commoditized graft portfolios toward suppliers that can prove fewer applications, less wastage, and lower total episode cost. MDXG and ORGO have the greatest near-term exposure to utilization and pricing normalization in chronic wounds; their reported growth rates should be discounted until 2026 claims data establishes whether volume offsets lower realized revenue per application. By contrast, SOLV, SNN and COLO.B have broader hospital procurement relationships and balance sheets to absorb evidence-generation, contracting and manufacturing investments that smaller peers cannot.

Over the next 1-3 months, quarterly commentary on average selling price, applications per patient, payer mix, and gross margin—not aggregate wound-care revenue—will determine winners. The CMS reset creates a potential inventory/channel correction and clinician product-switching cycle, which can make 2026 results materially noisier than the underlying chronic-wound demand trend. A second-order beneficiary is IART: hospital-based complex reconstruction and surgical matrix demand can gain share as care pathways migrate away from office economics, although its broader elective-procedure exposure prevents a pure-play interpretation.

The consensus risk is treating the reimbursement change as uniformly negative for biologics. A standardized payment framework may ultimately consolidate the market around brands with outcomes data and efficient manufacturing, expanding strategic M&A multiples for scarce differentiated platforms. However, the market-research growth forecast is not independently investable evidence; the key falsifier for the consolidation thesis is sustained price erosion without a corresponding decline in treatment frequency or demonstrated hospital conversion by 1H27.

MDXG's proposed SMTI acquisition is strategically rational because it diversifies end markets, but financing introduces an asymmetric execution risk: leverage and integration costs could eliminate the earnings benefit if CMS-driven wound weakness persists. The relevant catalyst is definitive-close timing plus pro forma revenue retention and debt-service guidance; absent those disclosures, the deal should be treated as an event-driven watch rather than a standalone long.

Key Decisions for Investors

• Initiate a 6-12 month long SOLV / short MDXG pair, sized beta-neutral. SOLV has a more diversified acute-care channel and integration optionality, while MDXG faces greater reimbursement-transition and acquisition-financing sensitivity; target 15-20% relative return. Exit if MDXG demonstrates two consecutive quarters of stable wound ASPs and expanding gross margin, or if SOLV reports material Acera integration dilution.
• Maintain an underweight/short bias in ORGO into the next two earnings prints, but only on confirmation of declining revenue per application or reduced 2027 guidance. The catalyst window is 1-6 months as post-reset claims and commercial contracting emerge; cover on evidence that treatment volumes rise enough to preserve gross profit dollars despite lower reimbursement.
• Accumulate COLO.B on pullbacks for a 12-18 month consolidation thesis, with a smaller tactical long in SNN as a liquid proxy. Both can use hospital scale and differentiated portfolios to gain accounts from undercapitalized suppliers; reassess if US advanced-wound organic growth decelerates below mid-single digits or reimbursement policy is revised again.
• Keep MDXG-SMTI merger-arbitrage exposure limited until the definitive agreement, financing covenants, and regulatory timetable are independently confirmed. A post-announcement long SMTI/short MDXG spread is attractive only if the implied annualized spread exceeds 12% and committed financing remains unconditional; principal downside is a repricing or termination driven by weaker MDXG cash generation.
• Set an earnings-data alert for MDXG, ORGO, SOLV, SNN and IART: track ASP, gross margin, hospital/surgical revenue growth, Medicare mix, and applications per patient. These metrics—not market-size projections—will validate whether the sector is undergoing durable consolidation or simply broad-based reimbursement-driven deflation.